Kidney Cancer Trial, Recruiting (NCT05874921)

Kidney Cancer Trial, Recruiting NCT05874921 Sponsor: UroGen Pharma Ltd. Condition: Kidney Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05874921 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Kidney Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be an adult (18 years or older) and able to make your own decision about joining the trial.
You must have been diagnosed with a condition called UTUC (a type of cancer affecting the lining of the upper urinary tract).
You must have received at least one dose of a medication called JELMYTO after it was approved by the FDA on April 15, 2020.

Who may not be able to join:

People who are not able to give their own consent to participate, such as those who are incarcerated or living with dementia.
People who received any dose of JELMYTO (also known as UGN-101 or Mitogel) on or before April 15, 2020, before it was FDA-approved.
People who are currently pregnant or breastfeeding.
People who may not be able to follow the requirements of the study (confirm with trial site).
People with a physical or mental health condition that the study doctor believes would make participation unsuitable (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yair Lotan, MD, UT Southwestern Medical Center at Dallas

Phone: 855-987-6436

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05874921

Sponsor: UroGen Pharma Ltd.

Phase: Not Applicable

Status: Recruiting

Condition: Kidney Cancer

Trial contact: 855-987-6436

More information: https://clinicaltrials.gov/study/NCT05874921

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be an adult (18 years or older) and able to make your own decision about joining the trial.
You must have been diagnosed with a condition called UTUC (a type of cancer affecting the lining of the upper urinary tract).
You must have received at least one dose of a medication called JELMYTO after it was approved by the FDA on April 15, 2020.

Who may not be able to join:

People who are not able to give their own consent to participate, such as those who are incarcerated or living with dementia.
People who received any dose of JELMYTO (also known as UGN-101 or Mitogel) on or before April 15, 2020, before it was FDA-approved.
People who are currently pregnant or breastfeeding.
People who may not be able to follow the requirements of the study (confirm with trial site).
People with a physical or mental health condition that the study doctor believes would make participation unsuitable (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

UroGen Pharma Ltd.

Registry

ClinicalTrials.gov

Start date

17 November 2023

Est. completion

1 April 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rate of CR or no evidence of disease (NED) at first evaluation post-treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov